Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Results from the IFM 2014-01 trial: pomalidomide, dexamethasone & ixazomib in high-risk R/R myeloma

Xavier Leleu • 10 Jun 2022
EHA 2022
Multiple Myeloma Dexamethasone Ixazomib Pomalidomide
IFM 2014-01

Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, shares some results from the IFM 2014-01 trial, evaluating the safety and efficacy of pomalidomide, dexamethasone and ixazomib for the treatment of patients with high-risk, relapsed/refractory (R/R) myeloma. Prof. Leleu first provides some background information on the use of combination therapy in myeloma, and then highlights the safety and efficacy of this regimen and results obtained in this trial. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Janssen, Takeda, BMS, GSK

More from Xavier Leleu

2:15
IMAGE subgroup analysis: real-world experience of Isa-Pd in patients with R/R multiple myeloma
Xavier Leleu • 29 Sep 2023
3:47
MagnetisMM-3: correcting hypogammaglobulinemia & using Ig replacement therapy to reduce infections
Xavier Leleu • 29 Sep 2023
3:04
Individualizing treatment in transplant-eligible & transplant-ineligible NDMM
Xavier Leleu • 29 Sep 2023
6:14
Ongoing studies of elranatamab in frail patients & with DaraPomDex: MagnetisMM-3 & MagnetisMM-5
Xavier Leleu • 9 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals